

Application Serial No.
10/599,550

RECEIVED
CENTRAL FAX CENTER

Patent
20080-00008

DEC 11 2007

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) An examination method ~~conducted for the administration of an anticancer drug targeting a tumor-associated factor receptor, in order to evaluate usefulness of treatment with [[the]] an anticancer drug targeting a tumor-associated factor receptor when administered to a subject, said method comprising,~~
detecting in an analyte sample from the subject, in addition to the examination of the gene encoding the receptor, and/or the expressed product thereof of the receptor, and
detecting in said analyte sample the examination of the gene encoding a substance,
and/or the expressed product thereof, ~~of a substance that interacts~~ interacting with the receptor on the surface of and/or within the cell membrane,
wherein said substance interacts with the receptor to affect receptor expression or function.
2. (Previously presented) The examination method according to Claim 1, wherein the tumor-associated factor receptor is a cell growth factor receptor.
3. (Previously presented) The examination method according to the Claim 2, wherein the cell growth factor receptor is an epidermal growth factor receptor or a receptor belonging to an epidermal growth factor receptor family.
4. (Previously presented) The examination method according to Claim 3, wherein the receptor belonging to the epidermal growth factor receptor family is HER2/c-erbB-2.
5. (Previously presented) The examination method according to Claim 1, wherein the substance interacting with the receptor on the surface of and/or within cell membrane is a glycoprotein.

Application Serial No.
10/599,550

Patent
20080-00008

6. (Previously presented) The examination method according to Claim 5, wherein the glycoprotein is a mucin.
7. (Previously presented) The examination method according to Claim 6, wherein the mucin is mucin 4 (MUC4).
8. (Previously presented) The examination method according to Claim 1, wherein the anticancer drug is an antibody to the receptor.
9. (Previously presented) The examination method according to Claim 8, wherein the antibody is a humanized monoclonal antibody.
10. (Currently Amended) The examination method according to Claim 9, wherein the humanized monoclonal antibody is trastuzumab (HereceptinTM).
11. (Previously presented) A reagent for use in the examination method according to Claim 1.
12. (Currently amended) A reagent kit for use in the examination method according to Claim 1, comprising
a probe sufficiently complementary to the gene encoding said receptor and a probe sufficiently complementary to the gene encoding said substance, and a hybridization medium and/or a wash medium; or
an antibody which binds to the expressed receptor and an antibody which binds said substance.
13. (Previously presented) The examination method according to Claim 2, wherein the substance interacting with the receptor on the surface of and/or within cell membrane is a glycoprotein.

Application Serial No.
10/599,550

Patent
20080-00008

14. (Previously presented) The examination method according to Claim 3, wherein the substance interacting with the receptor on the surface of and/or within cell membrane is a glycoprotein.
15. (Previously presented) The examination method according to Claim 4, wherein the substance interacting with the receptor on the surface of and/or within cell membrane is a glycoprotein.
16. (Previously presented) The examination method according to Claim 2, wherein the anticancer drug is an antibody to the receptor.
17. (Previously presented) The examination method according to Claim 3, wherein the anticancer drug is an antibody to the receptor.
18. (Previously presented) The examination method according to Claim 4, wherein the anticancer drug is an antibody to the receptor.
19. (Previously presented) The examination method according to Claim 5, wherein the anticancer drug is an antibody to the receptor.
20. (Previously presented) The examination method according to Claim 6, wherein the anticancer drug is an antibody to the receptor.